Zydus Pharmaceuticals’ subsidiary-- Nesher Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) to market Oseltamivir Phosphate Capsules, USP in strengths of 30mg, 45mg and 75mg.
The drug will be produced at the Nesher Pharmaceuticals USA manufacturing facility located in St. Louis, MO, USA. It is an anti-viral used in the prevention and treatment of influenza virus infection. The estimated sales for Oseltamivir Phosphate Capsules is $382 mn as per IMS December 2016 MAT data.
The group has also received the final approval from the USFDA to market Linezolid Tablets USP, 600 mg. The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has nearly 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.50 |
| Dr. Reddys Lab | 1237.75 |
| Cipla | 1238.15 |
| Zydus Lifesciences | 941.45 |
| Lupin | 2330.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: